NCT01559935 · FLOW
Participant flow
Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.
- groups
- description
- Carfilzomib, Clarithromycin (Biaxin®), Lenalidomide (Revlimid®), and Dexamethasone (Decadron®) \[Car-BiRD\] Car Phase: carfilzomib: 45 mg/m2 IV on days 1, 2, 8, 9, 15 and 16 of each 28 day cycles. Dexamethasone: 20 mg orally on days 1, 2, 8, 9, 15 and 16 of a 28 day cycle, while receiving carfilzomib. BiRD Phase: Clarithromycin: 500 mg twice a day for each 28 day cycle of BiRD treatment. BiRD begins after carfilzomib treatment has been completed. Lenalidomide: 25 mg orally days 1-21 for each 28 day cycle of BiRD treatment. BiRD begins after carfilzomib treatment has been completed. Dexamethasone: 40 mg orally on days 1, 8, 15 and 22 of each 28 day cycle of BiRD treatment. BiRD begins after carfilzomib treatment has been completed. Maintenance Phase: Lenalidomide: 10 mg orally on days 1-21 or each 28 day cycle of maintenance. Maintenance begins after BiRD treatment has been completed.
- id
- FG000
- title
- Car-BiRD Therapy
- periods
- drop Withdraws
- reasons
- group Id
- FG000
- num Subjects
- 4
- type
- Toxicity
- reasons
- group Id
- FG000
- num Subjects
- 1
- type
- Death
- reasons
- group Id
- FG000
- num Subjects
- 2
- type
- Lack of Efficacy
- reasons
- group Id
- FG000
- num Subjects
- 1
- type
- Lost to Follow-up
- reasons
- group Id
- FG000
- num Subjects
- 1
- type
- Physician Decision
- reasons
- group Id
- FG000
- num Subjects
- 2
- type
- Withdrawal by Subject
- reasons
- group Id
- FG000
- num Subjects
- 1
- type
- Per protocol
- reasons
- group Id
- FG000
- num Subjects
- 1
- type
- Insurance
- reasons
- group Id
- FG000
- num Subjects
- 1
- type
- non-compliance
- milestones
- achievements
- group Id
- FG000
- num Subjects
- 72
- type
- STARTED
- achievements
- group Id
- FG000
- num Subjects
- 58
- type
- COMPLETED
- achievements
- group Id
- FG000
- num Subjects
- 14
- type
- NOT COMPLETED
- title
- Car Phase
- drop Withdraws
- reasons
- group Id
- FG000
- num Subjects
- 1
- type
- Toxicity
- reasons
- group Id
- FG000
- num Subjects
- 1
- type
- Lack of Efficacy
- reasons
- group Id
- FG000
- num Subjects
- 2
- type
- Withdrawal by Subject
- milestones
- achievements
- group Id
- FG000
- num Subjects
- 58
- type
- STARTED
- achievements
- group Id
- FG000
- num Subjects
- 54
- type
- COMPLETED
- achievements
- group Id
- FG000
- num Subjects
- 4
- type
- NOT COMPLETED
- title
- BiRD Phase
- drop Withdraws
- reasons
- group Id
- FG000
- num Subjects
- 28
- type
- Remains on study
- reasons
- group Id
- FG000
- num Subjects
- 1
- type
- Toxicity
- reasons
- group Id
- FG000
- num Subjects
- 18
- type
- Lack of Efficacy
- reasons
- group Id
- FG000
- num Subjects
- 5
- type
- Withdrawal by Subject
- reasons
- group Id
- FG000
- num Subjects
- 2
- type
- Non-compliance
- milestones
- achievements
- group Id
- FG000
- num Subjects
- 54
- type
- STARTED
- achievements
- group Id
- FG000
- num Subjects
- 0
- type
- COMPLETED
- achievements
- group Id
- FG000
- num Subjects
- 54
- type
- NOT COMPLETED
- title
- Maintenance Phase
- pre Assignment Details
- Two subjects were ineligible and therefore never started treatment.
Complete source fields
- groups
- description
- Carfilzomib, Clarithromycin (Biaxin®), Lenalidomide (Revlimid®), and Dexamethasone (Decadron®) \[Car-BiRD\] Car Phase: carfilzomib: 45 mg/m2 IV on days 1, 2, 8, 9, 15 and 16 of each 28 day cycles. Dexamethasone: 20 mg orally on days 1, 2, 8, 9, 15 and 16 of a 28 day cycle, while receiving carfilzomib. BiRD Phase: Clarithromycin: 500 mg twice a day for each 28 day cycle of BiRD treatment. BiRD begins after carfilzomib treatment has been completed. Lenalidomide: 25 mg orally days 1-21 for each 28 day cycle of BiRD treatment. BiRD begins after carfilzomib treatment has been completed. Dexamethasone: 40 mg orally on days 1, 8, 15 and 22 of each 28 day cycle of BiRD treatment. BiRD begins after carfilzomib treatment has been completed. Maintenance Phase: Lenalidomide: 10 mg orally on days 1-21 or each 28 day cycle of maintenance. Maintenance begins after BiRD treatment has been completed.
- id
- FG000
- title
- Car-BiRD Therapy
- periods
- drop Withdraws
- reasons
- group Id
- FG000
- num Subjects
- 4
- type
- Toxicity
- reasons
- group Id
- FG000
- num Subjects
- 1
- type
- Death
- reasons
- group Id
- FG000
- num Subjects
- 2
- type
- Lack of Efficacy
- reasons
- group Id
- FG000
- num Subjects
- 1
- type
- Lost to Follow-up
- reasons
- group Id
- FG000
- num Subjects
- 1
- type
- Physician Decision
- reasons
- group Id
- FG000
- num Subjects
- 2
- type
- Withdrawal by Subject
- reasons
- group Id
- FG000
- num Subjects
- 1
- type
- Per protocol
- reasons
- group Id
- FG000
- num Subjects
- 1
- type
- Insurance
- reasons
- group Id
- FG000
- num Subjects
- 1
- type
- non-compliance
- milestones
- achievements
- group Id
- FG000
- num Subjects
- 72
- type
- STARTED
- achievements
- group Id
- FG000
- num Subjects
- 58
- type
- COMPLETED
- achievements
- group Id
- FG000
- num Subjects
- 14
- type
- NOT COMPLETED
- title
- Car Phase
- drop Withdraws
- reasons
- group Id
- FG000
- num Subjects
- 1
- type
- Toxicity
- reasons
- group Id
- FG000
- num Subjects
- 1
- type
- Lack of Efficacy
- reasons
- group Id
- FG000
- num Subjects
- 2
- type
- Withdrawal by Subject
- milestones
- achievements
- group Id
- FG000
- num Subjects
- 58
- type
- STARTED
- achievements
- group Id
- FG000
- num Subjects
- 54
- type
- COMPLETED
- achievements
- group Id
- FG000
- num Subjects
- 4
- type
- NOT COMPLETED
- title
- BiRD Phase
- drop Withdraws
- reasons
- group Id
- FG000
- num Subjects
- 28
- type
- Remains on study
- reasons
- group Id
- FG000
- num Subjects
- 1
- type
- Toxicity
- reasons
- group Id
- FG000
- num Subjects
- 18
- type
- Lack of Efficacy
- reasons
- group Id
- FG000
- num Subjects
- 5
- type
- Withdrawal by Subject
- reasons
- group Id
- FG000
- num Subjects
- 2
- type
- Non-compliance
- milestones
- achievements
- group Id
- FG000
- num Subjects
- 54
- type
- STARTED
- achievements
- group Id
- FG000
- num Subjects
- 0
- type
- COMPLETED
- achievements
- group Id
- FG000
- num Subjects
- 54
- type
- NOT COMPLETED
- title
- Maintenance Phase
- pre Assignment Details
- Two subjects were ineligible and therefore never started treatment.
Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f
Preserved source evidence · Not medical advice
Triangle